JPRN-jRCT2080223357未知1 期
A Phase 1 Study of the Safety and Tolerability of BMS 986148 in Subjects With Advanced and/or Metastatic Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Subject with advanced and/or metastatic solid tumors which are expected to express mesothelin who received the previous treatment
- •Must have measurable tumor per Response Evaluation Criteria in Solid Tumors
- •(RECIST) or modified RECIST for malignant pleural mesothelioma
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
排除标准
- •Cancer metastases in the brain
- •Uncontrolled or significant cardiovascular disease
- •Moderate eye disorders
- •Moderate peripheral neuropathy
- •Known past or active hepatitis B or C infection
研究者
相似试验
未知
1 期
Study of BMS-986012 in Subjects With Small Cell Lung CanerSmall Cell Lung CancerJPRN-jRCT2080223369Bristol-Myers Squibb K.K.18
招募中
1 期
utetium-177-anti-Programmed Cell Death-Ligand 1 single domain antibodies (177Lu-anti-PD-L1 sdAb) in metastatic non-small cell lung cancerMetastatic Non-small Cell Lung CancerCancer - Lung - Non small cellACTRN12623000959673Radiopharm Theranostics Ltd23
已完成
不适用
A phase I study of the safety, tolerability, and antitumor activity of escalating doses of combretastatin A4 phosphate given in combination with bevacizumab to subjects with advanced solid tumorsAdvanced solid tumoursSolid tumoursCancerISRCTN96787846OXiGENE, Inc. (USA)12
撤回
1 期
Safety and tolerability of the Traditional Chinese Medicine Formulation GOPAC in patients with advanced malignancyAdvanced malignancy (palliative)Cancer - Other cancer typesACTRN12609000652279Sydney South West Area Health Service70
未知
1 期
A Study to Evaluate the Safety and Tolerability of Subcutaneous Treprostinil and Pharmacokinetics of a Novel LY900014 Formulation in Healthy Japanese Subjects (I8B-JE-ITRK)HealthyJPRN-jRCT2080223225Eli Lilly Japan K.K.